The therapeutic landscape of multiple myeloma (MM) has undergone a remarkable evolution over the past 2 decades. The development and application of novel agents and new generations of drugs, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibody–based therapies, have resulted in improved prognosis and extended survival of patients with MM. Although these therapeutic advances are opportune and transformative, they add complexity to the MM clinical algorithms.
This resource guide is a review of bispecific antibodies, one of the new therapies currently being studied in clinical trials for patients with relapsed/refractory MM (RRMM), and best practices for oncology nurses and nurse and patient navigators, social workers, care coordinators, and advanced practice providers in supporting patients with RRMM who may be eligible for bispecific antibody–based treatment.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® | PO Box 563, Cranbury, NJ 08512 |
AONN+ DBA AONN+ is a 501(c)(6) organization under federal tax guidelines. AONN+ Foundation for Learning, Inc. a 501(c)(3) organization under federal tax guidelines.
AONN+ Advantage, LLC, a wholly owned subsidiary of AONN+.